The KLF1 transcriptional regulator is essential for normal red blood cell differentiation, and a particular mutation in this factor is associated with congenital dyserythropoietic anaemia. The Nan mutant mouse, in which the same amino acid is mutated and which displays a semi-dominant phenotype, serves as a valuable model for this disorder. It is known that the mutant protein, Nan-KLF1, can only bind a subset of target sites as compared with the wild type, and this leads to changes in downstream gene expression in heterozygous animals – due at least partly to effects of Nan-KLF1 on the target genes whose sites it can no longer bind. James Bieker and colleagues have recently discovered that the Nan-KLF1 variant can also bind a target sequence not recognised by wild-type KLF1. Now (p. 430), they investigate the phenotypic consequences of this. Importantly, they observe neomorphic expression of a number of genes in Nan/+ heterozygotes, which appears to be due to ectopic binding of Nan-KLF1 to these new target sequences. The downstream genes affected include a number of secreted factors, such as hepcidin – a regulator of cellular iron use – and interferon regulatory factor 7 (IRF7). Thus, Nan heterozygosity in the erythropoietic lineage can confer systemic effects via the inappropriate expression of secreted factors.
Nan: neomorphic effects in neonatal anaemia
- Split-screen
- Views Icon Views
-
Article Versions Icon
Versions
- Version of Record 01 February 2017
- Share Icon Share
-
Tools Icon
Tools
- Search Site
Nan: neomorphic effects in neonatal anaemia. Development 1 February 2017; 144 (3): e0303. doi:
Download citation file:
Advertisement
Cited by
Call for papers: Uncovering Developmental Diversity
Development invites you to submit your latest research to our upcoming special issue: Uncovering Developmental Diversity. This issue will be coordinated by our academic Editor Cassandra Extavour (Harvard University, USA) alongside two Guest Editors: Liam Dolan (Gregor Mendel Institute of Molecular Plant Biology, Austria) and Karen Sears (University of California Los Angeles, USA).
Choose Development in 2024
In this Editorial, Development Editor-in-Chief James Briscoe and Executive Editor Katherine Brown explain how you support your community by publishing in Development and how the journal champions serious science, community connections and progressive publishing.
Journal Meeting: From Stem Cells to Human Development
Register now for the 2024 Development Journal Meeting From Stem Cells to Human Development. Early-bird registration deadline: 3 May. Abstract submission deadline: 21 June.
Pluripotency of a founding field: rebranding developmental biology
This collaborative Perspective, the result of a workshop held in 2023, proposes a set of community actions to increase the visibility of the developmental biology field. The authors make recommendations for new funding streams, frameworks for collaborations and mechanisms by which members of the community can promote themselves and their research.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.